OncoSil signs an exclusive distribution agreement with EDH Nuclear Medicine

/0 Comments/in /by

OncoSil has signed an exclusive distribution agreement with EDH specifically covering the Turkish market. With a population of 85 million, this country’s potential addressable market is already large and is expected to grow at a rapid pace over coming years.

EDH is a specialist healthcare services company that undertakes a wide range of activities including:

  • The sales and after-sales service of medical devices used in nuclear medicine
  • Sales and distribution of radiopharmaceuticals and radioisotopes, and
  • Sales and consultancy services of turnkey projects for nuclear medicine departments and radiopharmaceuticals production sites.

EDH’s geographic footprint today extends well beyond its home Turkish market, to also include Central and Eastern Europe, North Africa, Middle East, Gulf Countries and a number of other Turkic Republics.

EDH Nuclear Medicine & Healthcare Services General Manager Hasan Ulas Ozcan, said:

“We are delighted about our collaboration with the esteemed partners at OncoSil Medical. The inclusion of the OncoSil™ device in our portfolio marks a significant milestone, not only for our organization but also for pancreatic cancer patients in Turkey. We are confident that the uptake of the OncoSil™ device in Turkey will be rapid, mirroring the success we have witnessed with Lu-177 and Ac-225 therapies.”

OncoSil Medical CEO & Managing Director Nigel Lange, said:

“We are excited to be working with EDH Nuclear Medicine & Healthcare Services for Turkish market. This highly regarded company has a strong background in Nuclear Medicine and a reputation for being involved in innovative therapies. The Turkish healthcare market has big potential, and we know from prior experience that they tend to rapidly adopt novel therapies. Together with our partner EDH, we are aiming to launch the OncoSil™ device in the Turkish market in the upcoming months and provide this treatment option for pancreatic cancer patients in Turkey.

 

About OncoSil

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

About EDH

EDH stands as a preeminent leader in radiopharmacy and nuclear medicine, offering a comprehensive range of services encompassing cutting-edge device sales and after-sales support, radiopharmaceutical distribution, and turn-key project consultancy. With over a decade of experience, EDH possesses proprietary expertise in emerging technologies, regulatory compliance, and industry networking, ensuring clients access the forefront of innovation and compliance in the dynamic field of radiopharmacy and nuclear medicine.

 

EDH AND TERTHERA ENTERS INTO EXCLUSIVE DISTRIBUTION AGREEMENT FOR TERBIUM-161

/0 Comments/in /by

Agreement will enable a swift introduction of Tb-161 into Türkiye, Bulgaria and Azerbaijan, enabling the application of a novel radiopharmaceutical for cancer healthcare.

BREDA, 17 October 2023 – EDH Nükleer Tıp & Sağlık Hizmetleri (“EDH”), a trailblazer in the domain of radiopharmacy and nuclear medicine,and TerThera BV are pleased to announce the signing of an exclusive distribution agreement for the regions Türkiye, Bulgaria and Azerbaijan.

Terbium-161, a carrier free lanthanide produced by neutron activation, is a highly promising radionuclide for Radioligand Therapy (RLT) exhibiting comparable chemical characteristics to known radiolanthanides that has the potential, due to highest addition of Auger electronic emission with a higher linear energy transfer, to improve anti-tumor capabilities for primary and (micro)metastasized cancers. EDH took the initiative to first introduce Terbium-161 into Türkiye enabling both preclinical and clinical research.

“I am absolutely thrilled about this collaboration with our esteemed partners at Terthera. Their invaluable contributions and expertise have played a pivotal role in bringing this groundbreaking technology to fruition.The potential of this partnership is truly unparalleled, and though there’s an ambitious journey ahead, the future shines brilliantly clear before us”. said Hasan Ulaş Özcan, General Manager of EDH. “I also want to express my heartfelt gratitude to our exceptional team at EDH. Their hard work, dedication, and unwavering commitment have been instrumental in making this collaboration with Terthera a reality. Together, we are forging a path toward an incredibly promising future”

Not only will EDH further increase their efforts to make Terbium-161 widely available in each region but will greatly support in the generation of dire needed clinical evidence for the application of Terbium-161 for RLT that will be shared in time with the global community of the Nuclear Medicine.

“In both my professional and private life, I have always had a warm heart towards Türkiye. It is a fantastic country with a very strong presence in nuclear medicine. One of the first countries to widely adopt Ga-68 PET diagnostics and RLT. We are seeing a bright future in our collaboration with EDH, a company with a long and fruitful experience in the nuclear medicine industry” said Philippe van Overeem, CEO of TerThera. “The ideas EDH initiated to launch Tb-161 in Türkiye, Azerbaijan and Bulgaria are truly remarkable and we foresee a very fruitful and long term relationship”

About TerThera BV

TerThera is a radionuclide production focussed company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in oncology and nuclear medicine.

About EDH

EDH stands as a preeminent leader in radiopharmacy and nuclear medicine, offering a comprehensive range of services encompassing cutting-edge device sales and after-sales support, radiopharmaceutical distribution, and turn-key project consultancy. With over a decade of experience, EDH possesses proprietary expertise in emerging technologies, regulatory compliance, and industry networking, ensuring clients access the forefront of innovation and compliance in the dynamic field of radiopharmacy and nuclear medicine.

For more information

Gen Era and EDH have joined forces

/in /by

Gen Era Diagnostics and EDH Nuclear Medicine and Healthcare Services have joined forces by bringing together their expertise in personalized diagnosis and treatment.

 

Gen Era, a leading genomics services company for Next Generation Sequencing (NGS), Molecular Biology, Bioinformatics and Life Sciences, moving on to shape the future of these projects from today, with technical knowledge and protocols covering a wide range of applications, as one of the first service providers in Turkey in the field of NGS. Expanding the geographies, it serves by offering to its stakeholders short turnaround times, competitive pricing and unmatched scientific support, Gen Era reinforces its pioneering role in the development of innovative products with RefGen, which it has recently acquired.

EDH, the authorized representative of the world’s leading companies in the nuclear medicine industry in more than 20 countries; operates in Turkey, Europe and the Middle East with its personalized cancer diagnosis and treatment products. In addition to its sales, distribution and technical service activities of radiopharmaceutical production, quality control and imaging equipment, EDH offers leading products used in targeted therapy to the use of researchers thanks to its business partners in the USA and continues to develop new products with its business partners in Europe.

With the synergy brought by the merger, Gen Era will strengthen its position in the global market with bioinformatics software, Next Generation Sequencing solutions and niche products in personalized oncology to complete the value chain in the fields of molecular/genetic diagnosis and targeted therapy, which are becoming increasingly important in today’s world. The goal is to be more active in markets outside Turkey with a fast and strong geographical growth strategy, including potential inorganic growth in the near future. After the restructuring, activities in the field of nuclear medicine and radiotheranostics will continue under the existing EDH brand.

Gen Era Managing Partners Alper Emrah İşeri and Murat Topaloğlu commented regarding the merger:

“While we increase our knowledge in niche areas thanks to the complementary products and services of EDH and Gen Era, we believe that this merger will add great strength and value to us in our journey to open up to global markets. In addition to the products offered to the market by EDH, especially in the field of personalized oncology, we are excited to be able to offer innovative products to all our stakeholders with a holistic approach and the use of our diagnostic solutions that we are developing within Refgen. In addition, we think that the visionary approach of both companies, good relations with their stakeholders and having core values ​​such as business ethics will be very important for the success of the new structure.”

EDH Founder and General Manager Hasan Ulaş Özcan also commented:

“We are very happy to be a part of the Gen Era family, which has gained a well-deserved appreciation in the national and international arena for its extraordinary development and achievements in the fields of genetics and life sciences. We are excited to start our journey with the aim of being among the important players of the future healthcare within Gen Era thanks to our team especially experienced in the nuclear medicine, medical device and clinical research sectors who has developed long-term relationships with global players.”

 

www.gen-era.com.tr   |    www.edhmed.com

 

 

 

SHINE and EDH enter distribution agreement for SHINE’s non-carrier added Lu-177

/in /by

JANESVILLE, Wis. & ISTANBUL Turkey, May 25, 2021 – EDH Nuclear Medicine and Healthcare Services Ltd. Co. and SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries.

 

Under the agreement, EDH will sell and distribute SHINE’s non-carrier-added, cGMP lutetium-177, or Lu-177, manufactured in Janesville, Wis.

 

Lu-177 is a low-energy beta-particle emitter that works by directly irradiating cancer cells after being delivered to the cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers and also shows promise for the treatment of metastatic prostate and other cancers. SHINE’s Lu-177 production process enables the company to produce the high specific activity, non-carrier-added Lu-177 required by today’s customers.

 

“At EDH, we are keen to provide state-of-the-art theranostic products and solutions to our stakeholders and SHINE’s n.c.a Lu-177 will enable us to offer high specific activity Lu-177 to patientswhile addressing hospitals’ risks associated with waste management ,” said Hasan Ulas Ozcan, general manager of EDH Nuclear Medicine and Healthcare Services. “We are happy to partner with an innovative company like SHINE, which is aiming to become the world’s leading producer of medical isotopes, and we hope to extend our regions of operation with SHINE after successfully launching SHINE’s n.c.a Lu-177 in selected countries.”

 

“SHINE’s Lu-177 has the potential to improve the patient outcomes around the world with certain cancers,” said Katrina Pitas, vice president and general manager of SHINE Therapeutics. “EDH is a strong partner for SHINE. Hasan and his team know the Eurasia region well and we look forward to working with them to ensure patients have access to this promising therapeutic isotope.”

 

About EDH Nuclear Medicine and Healthcare Services

 

EDH is the most innovative Service Integrator in the field of nuclear medicine and oncology offering state-of-the-art solutions. EDH currently handles sales and marketing of selected radiopharmaceuticals and radioisotopes as well as sales and after sales support of equipment used in nuclear medicine and niche segments of oncology. EDH also offers turnkey setup of radiopharmaceutical manufacturing plants and nuclear medicine departments compliant to EU/USFDA cGMP.

 

About SHINE Medical Technologies

 

SHINE is a nuclear technology company committed to improving the lives of patients around the world. The company is focused initially on the commercialization of medical isotopes, including molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer and other diseases, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcomes for some cancer patients. SHINE has created isotope production processes that will deliver products to benefit physicians and patients and help solve critical supply problems in the United States and markets in Europe and around the world. SHINE has a long-term strategy to solve some of humanity’s biggest problems and advance our vision for progressively broad and impactful uses of nuclear technology. For more information, please visit our website at www.shinemed.com.

Hasan Ulaş Özcan has been honored to serve as an Ambassador of Oncidium foundation

/2 Comments/in /by

Hasan Ulaş Özcan, General Manager of EDH Nuclear Medicine & Healthcare Services and experienced executive served Nuclear Medicine society, has been honored to serve as Ambassador of the Oncidium foundation in Turkey.

“I have been personally trying hard to spread the word and reach more patients who may benefit from the Radiotheranostics and create awareness in the society. At a certain point I thought to serve community in a better way by joining our efforts with the people sharing the same passion under the umbrella of the Oncidium foundation. Together with Oncidium foundation, we aim to leverage Radiotheranostics as alternatives for cancer therapy and providing support to accelerate global access. This is a voluntary assignment and the collective efforts we will be having to create a bigger impact is priceless. I appreciate and thank Oncidium foundation team allowing me to be a part of this great cause” commented Hasan Ulaş Özcan. 

“We are very honored to have Mr. Hasan Ulaş Özcan as part of the Oncidium foundation Ambassadors network. Our mission is to support and promote the development of Radiotheranostics for cancer therapy, worldwide. Thus, it requires having local representation, notably in Turkey, where Radiotheranostics are becoming more and more available and important” stated Rebecca Lo bue, General Manager of the Oncidium foundation. 

About EDH Nuclear Medicine and Healthcare Services:

EDH is one of the most innovative Service Integrators in the field of Nuclear Medicine and oncology offering state of the art solutions. EDH currently handles sales and marketing of selected radiopharmaceuticals and radioisotopes as well as sales and after sales support of equipment used in Nuclear Medicine and niche segments of oncology. EDH also offers turnkey setup of radiopharmaceutical manufacturing plants and nuclear medicine departments compliant to EU/USFDA GMP.

About the Oncidium foundation:

The Oncidium foundation was created in 2011 by Dr. Richard Zimmermann to support and promote the development of Radiotheranostics worldwide. The foundation’s priorities include raising awareness about Radiotheranostics among patients, practitioners, and the general public; investing in research and scholarships; encouraging the development of new radiopharmaceuticals for therapy; supporting clinical best practice and enhancing access for patients, globally.

EDH inks the deal for exclusive distribution of Elysia-Raytest products

/in /by

EDH Nuclear Medicine and Healthcare Services is pleased to announce that they have entered into a strategic agreement with Elysia-Raytest S.A. that makes them their authorized distributor for selected countries. 

The deal involves the exclusive distribution and service support of  Elysia-Raytest products in the countries where EDH has active presence including but not limited to Albania, Azerbaijan, Bangladesh, Bosnia-Herzegovina, Croatia, Georgia, Jordan, Kyrgyzstan, Kosovo, Lebanon, Macedonia, Montenegro, Pakistan, Slovenia, Serbia, Turkey, Turkmenistan, Tajikistan, Uzbekistan as well as additional 16 non-exclusive countries.

“Elysia-Raytest is a highly innovative and progressive manufacturer and we are proud to be able to leverage our proven expertise and experience in nuclear medicine and oncology to help bring these virtues into focus. We have already been working with Elysia-Raytest in some selected countries and unique projects and this expansion of our collaboration enables EDH to serve to a broader geographical reach with state of the art Products. We are also keen to add new complimentary products to our portfolio with other great manufacturers in very near future which will help us to create an integrated solution platform as being the most innovative service integrator” commented Hasan Ulas Ozcan, General Manager of EDH Nuclear Medicine and Healthcare Services.

About EDH Nuclear Medicine and Healthcare Services:

EDH is  the most innovative Service Integrator in the field of nuclear medicine and oncology offering state of the art solutions. EDH currently handles sales and marketing of selected radiopharmaceuticals and radioisotopes as well as sales and after sales support of equipment used in nuclear medicine and niche segments of oncology. EDH also offers turnkey setup of  radiopharmaceutical manufacturing plants and nuclear medicine departments compliant to EU /USFDA GMP .

About Elysia-Raytest:

Elysia-Raytest is a competent and reliable partner for the global community in nuclear medicine and Radio Therapy synthesis and Quality Control. The reputation of Elysia- Raytest is based on the supply of high-quality hard- and software solutions and services for quality control (QC) laboratories and PET tracer production synthesizers . From metabolism research in pharmaceutical and agrochemical research to nuclear medicine and PET, Elysia-Raytest supplies state-of-the-art devices and integral GMP solutions.

Elysia-Raytest GmbH achieved ISO 9001 certification which is the highest quality system of the global ISO 9000 series of quality assurance standards. It was developed by the International Organization for Standardization (ISO).

With ISO 9001 certification, Elysia-Raytest established a definitive quality process that ensures reliability and consistency from the initial idea up to the release of innovative new products, furthering the company’s position within the international scientific community.